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Summary: Urinary kallikrein activity in rats and man was measured by an amidolytic assay using the chromogenic
tripeptide/P-valyl-leucyl-arginine-p-nitroanilide (S 2266). The sensitivity of the assay permits the measurement of
3.5 to 250 mKU of purified porcine pancreatic kallikrein. The intraassay coefficient of variation was 1.6 ± 0.3 %
and the interassay coefficient of variation 7.4 ± 0.9%. No changes in kallikrein activity were found in urine samples
kept for 7 days at 4 °C or 14 months at —20 °C. Repeated freezing and thawing reduced kallikrein activity. Kallikrein
activity of the same urine samples was also estimated by means of a bradykinin radioimmunoassay, which determines
the kinins released during incubation of urine with partially purified dog kininogen (kininogenase activity). The
urinary kallikrein activity assayed by means of these two methods showed a high correlation with coefficients of
r = 0.9314 for rat urine (p < 0.001) and r = 0.8002 for human urine (p < 0.001).
Anwendung eines chromogenen Tripeptids als Substrat für die Bestimmung der Kallikrein-Aktivität im Urin von Ratte
und Mensch
Vergleich des amidolytischen Assays mit dem Bradykinin Radioimmunoassay
Zusammenfassung: Die Kallikrein-Aktivität im Urin von Ratte und Mensch wurde durch einen amidolytischen Assay
bestimmt. Als Substrat diente das chromogene Jripeptid ^-Valyl-I^ucyl^Arginm-p-nitroanilid (S 2266). Die untere
Nachweisgrenze für glanduläres Kallikrein (Schweinepankreas-Kallikrein) lag in dem angewandten Verfahren bei 3,5
bis 250 Millieinheiten der biologischen Aktivität. Die Variationskoeffizienten'betrugen in der Serie 1,6 ± 0,3%,
zwischen den Serien 7,4 ± 0,9%. Die Kallikrein-Aktivität im Urin blieb sowohl über 7 Tage bei 4 °C als auch über
14 Monate bei —20 °C unverändert meßbar. Wiederholtes Einfrieren und Auftauen verminderte die Kallikrein-Aktivi-
tät. Die Bestimmung der Kallikrein-Aktivität im Urin wurde gleichzeitig sowohl mit dem amidolytischen Assay als
auch mit einem Radioimmunoassay für Bradykinin durchgeführt; durch letzteren wird die Kininogenase-Aktivität des
Kallikreins gemessen. Die mit beiden Verfahren erhaltenen Werte der Kallikrein-Aktivität im Urin korrelierten eng mit-
einander. Es ergaben sich Korrelationskoeffizienten von r = 0,9314 (p < 0,001) für die Messungen im Rattenurin und
r = 0,8002 (p < 0,001) für die Bestimmungen im Menschenurin.
Introduction determination, either a bioassay (2) or a radioimmuno-
„ , , „ , , „ , , . , , assay for bradykinin have been used (3,4). Direct kalli-
Glandular kaUikreins are senne proteases, which cleave ^
 radioimmunoassays have aiso been developed (5, 6,
kallidin from high and low molecular weight kininogen.
Urinary kallikrein belongs to the glandular kallikreins .
and is identical to renal kallikrein (1) which is secreted
 l} Abbreviations
into the distal tubular fluid. The content of kallikrein in Bz-Z,-Arg-O-Et: N*-benzoyl-£-arginine ethyl ester
urine can be estimated either by means of the esterolytic Tos-£-Arg-O-Me: Tosyl-£-arginine methyl ester
activity it exerts on substrates like To's-£-Arg-O-Me or H-u-Val-Leu-Arg-p-nitroaniUde: H-fl-valyl-leucyl-arginme-
~ ' ^' ' , , . . , , p-nitroamlide
- ,-Arg-OrEt or by assaying the kinins released
 KU: kanyaein units
during the incubation with kininogen. For the latter KIU: kallikrein inactivator units
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7, 8). A synthetic chromogenic amide substrate for
kallikrein is now available (H-£-Val-Leu-Arg-p-nitro-
anilide, Kabi GmbH, M nchen). The cleavage of the
chromophore p-nitroaniline from the tripeptide is
caused by the amidolytic activity of glandular kalli-
krein. The kinetics of this enzymatic reaction are
similar to those of kallikrein with its natural substrate
(9). Other serine proteases including plasma kallikrein
can also cleave the synthetic substrate, but have much
lower specific activity than glandular kallikrein (10).
Therefore, this assay is more selective than the estero-
lytic assays, and the determination of glandular kalli-
krein activity by the amidolytic assay is easier and less
time-consuming than by bioassay or radioimmuno-
assays. To study the validity of the newly developed
method, the enzyme concentration in urine deter-
mined by this method was compared to the concentra-
tion measured by the well established bradykinin
radioimmunoassay (4) and the correlation of data
obtained with both methods was estimated.
Material and Methods
Rat urine was collected in metabolic cages over a period of
24 hours. At the end of the collection period, urine volume
was measured and the urine frozen in two portions and stored
at —20 °C. For assaying kallikrein, urine was thawed at 4 °C,
centrifuged for 10 minutes at 3000 £ and then diluted 150
times by adding distilled water. Human urine was collected
at 4 °C over 24 hours from normal volunteers and patients
with essential hypertension. The urine was frozen at the end
of the collection period and stored at -20 °C until measurement.
After thawing and centrifugation, kallikrein activity was mea-
sured in urine undiluted or diluted twice with distilled water.
Kallikrein activity was estimated by bradykinin radioimmuno-
assay (3, 4) by incubating 100 ìÀ diluted urine with partially
purified kininogen from dog plasma (5 mg in 900 ìÀ 0.1 mol/1
Tris-HCl buffer) for 20 minutes at pH 8.5 and 37 °C in the
presence of kininase inhibitor o-phenanthroline (3 mmol/1).
The kininogen preparation used had neither kallikrein-like nor
kininase activity under the conditions of the assay. An inhibition
of added porcine kallikrein could not be detected. The incuba-
tion was stopped by the addition of 4 ml ethanol (990 ml/1) to
100 ì! of incubate. After centrifugation and evaporation of the
supernatant to dryness, the residue was dissolved in 600 ìÀ
0.1 mol/1 Tris-HCl buffer, pH 7.4 and kinin content was measured
by radioimmunoassay as reported (4). Urinary kallikrein activity
was expressed as jug bradykinin per minute incubation per ml
urine. The intraassay coefficient of variation was 5.5 ± 1.5%, the
interassay coefficient of variation 11.9 ± 1.3%. Antibradykinin
serum crossreacted with lysyl-bradykiriin (100%) and methionyl-
lysyl-bradykinin (85.1%). However, methionyl-lysyl-brady-
kinin is not a disturbing factor, since it is not produced at
the pH of the assay. The simultaneous measurement of , .
lysyl-bradykinin (kallidin) and bradykinin reveals the actual
kallikrein activity of the urine independently of its amino-
peptidase activity. Low molecular weight kininogen also cross-
reacts with the antibody (0.7%), but this crossreaction does
not disturb the measurement of kinins, since the kininogen
remaining in the incubation medium is precipitated by the
addition of ethanol. The blank of kininogen included in
each assay was always free of kinin-like immunoreactive
substances. No detectable crossreaction (< 0.001%) was found
with peptides unrelated to the kinins (angiotensin I, angiotensin
II, angiotensin III, substance P, neurotensin, Leu-enkephalin,
saralasin, bradykinin potentiator Â and C, eledoisin).
Urinary kallikrein activity was also determined by cleavage
of the chromophore p-nitroaniline enzymatically from the
chromogenic tripeptide substrate S 2266 (H-0-Val-Leu-Arg-
p-nitroanilide, Kabi Diagnostika GmbH, M nchen). The method
used was slightly modified from that reported by Amundsen
et al. (9). Urine was incubated with substrate (1.5 mmal/1
in the presence or absence of aprotinin (50 KIU, Trasyloi · )
for 30 minutes at 37 °C. Tris-HCl, pH 8.2 (0.2 mol/1) was
used as buffer. The reaction was stopped by addition of
500 g/1 acetic acid. The activity of urinary kallikrein was
calculated according to Amundsen (9,11) and given in units
per liter (U/l), one unit being the amount of glandular kalli-
krein which cleaves one ìðéïß substrate per minute incubation
at the given conditions. Values of kallikrein activity are given as
mean ± SEM. Significance was calculated by Student's t-test;
for correlations significance was tested against zero.
Results
In the amidolytic assay, the amount of the chromo-
phore, p-nitroaniline, cleaved during incubation was
linearly related to the incubation time up to 120 minutes
as well s to the amount of active enzyme. The results
obtained by the amidolytic assay followed a straight
line from 3.5 up to 250 milliunits kallikrein, using
porcine pancreatic kallikrein as standard. The colour
of liberated p-nitroaniline was stable for at least 4 hours
(absorbance after stopping: 0.341 ± 0.03, absorbance
after 255 minutes storage at room temperature:
0.359 ± 0.029, n:3). The intraassay coefficient of
variation was 1.6 ± 0.3%, the interassay variation
7.4 ± 0.9%. The kallikrein activity in rat urine remained
unchanged during storage for 7 days at 4 °C (1st day:
2.03 ± 0.24; 3rd day: 2.10 ± 0.45; 7th day: 2.18 ± 0.48
U/l), when storage time was prolonged, all urines tested
lost their activity rapidly (11th day of storage at 4 °C:
1.00 ± 0.14 U/l, p < 0.005). Repeated freezing and
thawing caused a decrease in activity of urinary kalli-
krein, which was already significant after the first
freezing (p < 0.01, fig. 1). During storage of urine at
-20 °C, no changes of kallikrein activity were observed
over a period of 14 months (0.38 ± 0.07 U/Uvol vs.
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Fig. 1. Loss of urinary kallikrein catalytic activity in urine of
rats (n = 8) after freezing and thawing, which -was
repeated fivefold. Values are given as means ± SEM.
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0.41 ± 0.07 U/Uvol, n: 10). The measurement of urinary
kallikrein in rats by the amidolytic assay and by brady-
kinin radioimmunoassay was performed in urine of
normotensive rats, spontaneously hypertensive rats,
rats with deoxycorticosterone treatment (200 mg/kg
in silicone pellets s.c.), rats with renovascular hyper-
tension (aortic ligature) and rats with salt-loading
(20 g/1 NaCl as drinking fluid). The well established
changes in urinary kallikrein excretion such as enhance-
ment by deoxycorticosterone acetate (12, 13) or reduc-
tion by salt-loading (14, 15) were detected by both
methods with the same degree (tab. 1). The correlation
coefficient of the kallikrein activity for all groups of rats
investigated obtained by both methods are given in
table 2. The regression line calculated from the values
obtained in the normotensive control rats was
y = 0.042 ÷ + 0.07 (fig. 2), the slope of the regression
line was the same in all groups investigated. Also a high
correlation between both methods was found in urine
of normotensive and hypertensive humans (tab. 2).
Tab. 1. Comparison of urinary excretion determined by amidolytic assay and by bradykinin radioimmunoassay in rats with stimulated
renal kallikrein-kinin system by deoxycorticosterone acetate (200 mg/kg in silastic subcutaneously over 14 days; and with sup-
pressed activity of renal kallikrein by salt-loading (20 g/1 NaCl as drinking fluid over 7 days). Values are given in U/l
(mean ± SEM;.
Investigation
group
Determination
Amidolytic assay
S 2266
Bradykinin
radio imm unoassay
Salt-loading
Control
1.23 ± 0.10
25.50 ±1.88
20 g/1 NaCl
0.69 ± 0.04
p < 0.001
14.62 ± 0.76
p < 0.001
Deoxycorticosterone
Control
+ 10 g/1 NaCl
(n = 10)
0.59 ± 0.08
P
11.75 ± 2.66
P
Deoxycorticosterone
+ 10 g/1 NaCl
(n = 8)
1.21 ±0.14
< 0.001
25.1 3 ±3.66
<0.01
H
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Fig. 2. Correlation of urinary kallikrein activity measured
simultaneously by bradykinin radioimmunoassay (abscissa;
and by amidolytic assay (ordin re) in untreated normo-
tensive Wistar rats. The coefficient of correlation is
r = 0.9623 ( n = 58; ñ < 0.001) and the regression line is
y = 0.042 ÷ + 0.07.
Tab. 2. Coefficients of correlation between the values of urinary
kallikrein activity measured by both the bradykinin
radioimmunoassay and the amidolytic assay ir urine of
rats and man.
Significance for all groups tested: ñ < 0.001.
Group
Rats
Normotensive control rats
Spontaneously hypertensive rats
Renal hypertensive rats
Salt loading (20 g/1 saline)
Deoxycorticosterone
Man
Normotensive
Hypertensive
Number of
samples
185
58
20
45
26
36
36
25
Coefficient of
correlation
0.9314
0.9623
0.9361
0.9421
0.9303
0.8699
0.8002
0.8177
Discussion
The amidolytic assay using the chromogenic tripeptide
substrate H-Z)-Val-Leu-Arg-p-nitroanilide (S 2266) is a
convenient and sensitive method for the measurement
of urinary kallikrein activity. The assay may be con-
sidered as being selective for glandular kallikrein, since
the absorption of the sample is read against a blank, in
which kallikrein is inhibited by aprotinin (Trasylol®),
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which does not inhibit urokinase or bacterial enzymes
(9). Plasma kallikrein has a much lower specific activity
for the chromogenic substrate (10). Thus, plasma kalli-
krein would not disturb the measurement of urinary
(renal) kallikrein, even when small amounts of the big
molecule of plasma kallikrein could filter through the
glomeruli. In a previous investigation (8), the activity
of purified porcine pancreatic kallikrein measured by
the amidolytic assay was compared with the one deter-
mined in a newly developed esterolytic assay, and a
strong correlation between the values was found.
In urine, kallikrein activity was stable for seven days
at 4 °C and for 14 months at -20 °C. However, with
every freezing and thawing, the urine lost some kalli-
krein activity. Thus, it is advisable to avoid freezing
and thawing of urine before measurement if technically
possible, in order to test for the real activity of kalli-
krein activity in urine.
Both the kininogenase and the amidolytic assays measure
the kallikrein-like activity, but not the absolute amount
of renal kallikrein in urine. It cannot be excluded that
kallikrein measurement by either method is differently
affected by the presence of kallikrein inhibitors. How-
ever, the high correlation between kininogenase and ami-
dolytic activity observed suggests that both methods mea-
sure the same enzyme. The correlation was also found in
widely different experimental conditions such as salt-
loading, mineralocorticoid excess and renovascular
hypertension as well as spontaneous hypertension in
rats, and in low and high concentrated urine. The
sensitivity of the amidolytic assay for glandular kalli-
krein is as high as that of the esterolytic assays, but
the latter methods (Tos-i-Arg-O-Me, Bz-L-Arg-0-Et)
are less specific (4,16) than the assay of kininogenase
activity of kallikrein, while the amidqlytic assay appears
to be as specific as the kininogenase assay. The amido-
lytic assay is less difficult to perform than the radio
immunoassays and does not require expensive equip-
ment. So the amidolytic assay is adequate for the
measurement of urinary kallikrein activity in urine
of both experimental animals and man.
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